ORIC Pharmaceuticals is a privately held, clinical-stage oncology company focused on making cancer treatments more effective by addressing mechanisms of resistance. ORIC's lead asset, ORIC-101, is a potent and selective small-molecule antagonist of the glucocorticoid receptor. ORIC's pipeline targets other undisclosed mechanisms of oncology therapy resistance. ORIC's scientific founders are Drs. Charles Sawyers, MD, and Scott Lowe, PhD, who have strong records of discovering innovative treatments and targets in cancer.  The company has assembled strong leadership and scientific teams and a board with extensive experience in drug development and financing.  ORIC is funded by leading biotechnology investors, including The Column Group, Topspin Partners, OrbiMed Advisors, EcoR1 Capital, Fidelity Management & Research Company, Trinitas Capital, Foresite Capital, Taiho Ventures, Memorial Sloan Kettering, Kravis Investment Partners, NS Investment and City Hill Ventures. ORIC is headquartered in South San Francisco, California.

Biotechnology

Health Care

Pharmaceutical

Therapeutics

Oric Pharmaceuticals

Oric Pharmaceuticals' headquarters in South San Francisco, CA, United States

Jacob Chacko

Carmen Breslin

Dan Iazzetti

Pratik Multani

Christian V. Kuhlen

Matt Panuwat

Edna Chow Maneval

Dominic Piscitelli

Lori Friedman

Richard Heyman

Mardi C. Dier

Scott Lowe

Charles Sawyers

Lori Kunkel

Angie You

Steve L. Hoerter

Description

People (34)

Maria Luisa Jimenez

Tatyana Profis

Nicole Gunselman

Chelsea Chen

Claire Repellin

Idil Ulengin-Talkish

Siobhan K. McRee

Sandy Koppenol

Ajit Narang

Anthony Romero

Daniel Holycross

Daniel Shore

Rakesh Vekariya

Bob Warne

Brian Blank

Christopher Weber

Danial Barati

Htlcm Frank L Duong (ASCP)

Jared Moore

Jason B.

Joanna Wang

Krista Bowman

Kyle Edgar

Livia Ulicna

Alex Pankov

Amber Wang

Gina Andreatta

Siyu Liu

Kevin Sun

Zinnia Xu

Michael Cheung

Denisse Carvajal Maldonado

Tucker Roberts

Liliana Soroceanu

Jobs